Review



plasma low density lipoprotein cholesterol ldl c  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Novus Biologicals plasma low density lipoprotein cholesterol ldl c
    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) <t>Circulating</t> <t>low-density</t> <t>lipoprotein</t> <t>cholesterol</t> <t>(LDL-C)</t> and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.
    Plasma Low Density Lipoprotein Cholesterol Ldl C, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp3+25881/Low-density+Lipoprotein+Cholesterol%2FLDL-C+Assay+Kit+(Colorimetric)/bio_rxiv__64898__2026__03__20__713290-247-0-12
    Average 94 stars, based on 3 article reviews
    plasma low density lipoprotein cholesterol ldl c - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable Pcsk9 Silencing in a Clinically Relevant Delivery System"

    Article Title: Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable Pcsk9 Silencing in a Clinically Relevant Delivery System

    Journal: bioRxiv

    doi: 10.64898/2026.03.20.713290

    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) Circulating low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.
    Figure Legend Snippet: (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) Circulating low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.

    Techniques Used: Control, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

    (A) Body weights of 8–12-week-old female C57BL/6N mice following intravenous administration of 1 mg/kg RNA formulated in LUNAR ® . (B–D) Plasma levels of PCSK9 protein (B), low-density lipoprotein cholesterol (LDL-C) (C), and total cholesterol (D) measured at indicated time points post-dosing. (E) Comparison of therapeutic efficacy of different gene-modifying modalities on plasma PCSK9, LDL-C, and total cholesterol levels at day 30 post-dose. Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparisons test (* P < 0.05, *** P < 0.001). For PCSK9 comparisons, differences between groups not specifically indicated are all statistically significant ( P < 0.001). Error bars: SD.
    Figure Legend Snippet: (A) Body weights of 8–12-week-old female C57BL/6N mice following intravenous administration of 1 mg/kg RNA formulated in LUNAR ® . (B–D) Plasma levels of PCSK9 protein (B), low-density lipoprotein cholesterol (LDL-C) (C), and total cholesterol (D) measured at indicated time points post-dosing. (E) Comparison of therapeutic efficacy of different gene-modifying modalities on plasma PCSK9, LDL-C, and total cholesterol levels at day 30 post-dose. Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparisons test (* P < 0.05, *** P < 0.001). For PCSK9 comparisons, differences between groups not specifically indicated are all statistically significant ( P < 0.001). Error bars: SD.

    Techniques Used: Clinical Proteomics, Comparison, Drug discovery

    (A) Experimental design comparing the efficacy of epi-editor delivery between the Capelluti et al. study and Arcturus Therapeutics. Plasma was collected at the indicated time points (dots colored by time). (B) Plasma PCSK9 levels measured at each time point post-dosing. Data were normalized to the respective vehicle controls (PBS-treated mice for Capelluti et al. and LUNAR ® -formulated eGFP mRNA for Arcturus data). (C–E) Comparison of plasma PCSK9 (C), LDL-C (D), and total cholesterol (E) at day 30 post-dosing. Values were normalized to the respective vehicle controls. Error bars: SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test (* P < 0.05, ** P < 0.01, *** P < 0.001). Capelluti’s data were adapted from provided data in and Arcturus data were from the current study.
    Figure Legend Snippet: (A) Experimental design comparing the efficacy of epi-editor delivery between the Capelluti et al. study and Arcturus Therapeutics. Plasma was collected at the indicated time points (dots colored by time). (B) Plasma PCSK9 levels measured at each time point post-dosing. Data were normalized to the respective vehicle controls (PBS-treated mice for Capelluti et al. and LUNAR ® -formulated eGFP mRNA for Arcturus data). (C–E) Comparison of plasma PCSK9 (C), LDL-C (D), and total cholesterol (E) at day 30 post-dosing. Values were normalized to the respective vehicle controls. Error bars: SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test (* P < 0.05, ** P < 0.01, *** P < 0.001). Capelluti’s data were adapted from provided data in and Arcturus data were from the current study.

    Techniques Used: Clinical Proteomics, Comparison

    Related Articles

    other:

    Article Title: Maternal obesity induces activator protein 1‐mediated inflammatory response to impair embryonic neurogenesis
    Article Snippet: Serum lipid profiles, including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG), were analysed using commercial assay kits following the manufacturer’s instructions (cat. no. NBP3-25823, NBP3-25881 and NBP3-24542, Novus Biologicals, Centennial, CO, USA).

    Article Title: Maternal obesity induces activator protein 1‐mediated inflammatory response to impair embryonic neurogenesis
    Article Snippet: Serum lipid profiles, including high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C) and triglycerides (TG), were analysed using commercial assay kits following the manufacturer's instructions (cat. no. NBP3‐25823, NBP3‐25881 and NBP3‐24542, Novus Biologicals, Centennial, CO, USA).



    Similar Products

    plasma low density lipoprotein cholesterol ldl c  (Novus Biologicals)
    94
    Novus Biologicals plasma low density lipoprotein cholesterol ldl c
    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) <t>Circulating</t> <t>low-density</t> <t>lipoprotein</t> <t>cholesterol</t> <t>(LDL-C)</t> and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.
    Plasma Low Density Lipoprotein Cholesterol Ldl C, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp3+25881/Low-density+Lipoprotein+Cholesterol%2FLDL-C+Assay+Kit+(Colorimetric)/bio_rxiv__64898__2026__03__20__713290-247-0-12
    Average 94 stars, based on 1 article reviews
    plasma low density lipoprotein cholesterol ldl c - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    nbp3 25881  (Novus Biologicals)
    94
    Novus Biologicals nbp3 25881
    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) <t>Circulating</t> <t>low-density</t> <t>lipoprotein</t> <t>cholesterol</t> <t>(LDL-C)</t> and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.
    Nbp3 25881, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp3+25881/Low-density+Lipoprotein+Cholesterol%2FLDL-C+Assay+Kit+(Colorimetric)/10__1113_slash_jp289326-91-28-31
    Average 94 stars, based on 1 article reviews
    nbp3 25881 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    low density lipoprotein cholesterol  (Novus Biologicals)
    94
    Novus Biologicals low density lipoprotein cholesterol
    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) <t>Circulating</t> <t>low-density</t> <t>lipoprotein</t> <t>cholesterol</t> <t>(LDL-C)</t> and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.
    Low Density Lipoprotein Cholesterol, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp3+25881/Low-density+Lipoprotein+Cholesterol%2FLDL-C+Assay+Kit+(Colorimetric)/10__1096_slash_fj__202502000r-54-15-33
    Average 94 stars, based on 1 article reviews
    low density lipoprotein cholesterol - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    assay kits  (Novus Biologicals)
    94
    Novus Biologicals assay kits
    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) <t>Circulating</t> <t>low-density</t> <t>lipoprotein</t> <t>cholesterol</t> <t>(LDL-C)</t> and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.
    Assay Kits, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp3+25881/Low-density+Lipoprotein+Cholesterol%2FLDL-C+Assay+Kit+(Colorimetric)/pmc12571146-68-27-29
    Average 94 stars, based on 1 article reviews
    assay kits - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    low density lipoprotein cholesterol ldl c  (Novus Biologicals)
    94
    Novus Biologicals low density lipoprotein cholesterol ldl c
    Effect of fetal Intralipid infusion on serum metabolic parameters. (A) Serum glucose concentrations. (B) Serum triglyceride (TG) concentrations. (C) Serum total <t>cholesterol</t> concentrations. (D) Serum low‐density <t>lipoprotein</t> cholesterol (LDL‐C) concentrations. (E) Serum high‐density cholesterol (HDL‐C) concentration. (Control group: N = 2F, 6M; Intralipid‐treated group: N = 6F, 3M; data are presented as mean ± SD; * p < 0.05, ** p < 0.01).
    Low Density Lipoprotein Cholesterol Ldl C, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp3+25881/Low-density+Lipoprotein+Cholesterol%2FLDL-C+Assay+Kit+(Colorimetric)/pmc12571146-68-13-29
    Average 94 stars, based on 1 article reviews
    low density lipoprotein cholesterol ldl c - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) Circulating low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.

    Journal: bioRxiv

    Article Title: Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable Pcsk9 Silencing in a Clinically Relevant Delivery System

    doi: 10.64898/2026.03.20.713290

    Figure Lengend Snippet: (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) Circulating low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.

    Article Snippet: Plasma low-density lipoprotein cholesterol (LDL-C) was measured using a colorimetric assay kit (Novus Biologicals, Centennial, CO) following the manufacturer’s protocol, with samples loaded undiluted.

    Techniques: Control, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

    (A) Body weights of 8–12-week-old female C57BL/6N mice following intravenous administration of 1 mg/kg RNA formulated in LUNAR ® . (B–D) Plasma levels of PCSK9 protein (B), low-density lipoprotein cholesterol (LDL-C) (C), and total cholesterol (D) measured at indicated time points post-dosing. (E) Comparison of therapeutic efficacy of different gene-modifying modalities on plasma PCSK9, LDL-C, and total cholesterol levels at day 30 post-dose. Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparisons test (* P < 0.05, *** P < 0.001). For PCSK9 comparisons, differences between groups not specifically indicated are all statistically significant ( P < 0.001). Error bars: SD.

    Journal: bioRxiv

    Article Title: Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable Pcsk9 Silencing in a Clinically Relevant Delivery System

    doi: 10.64898/2026.03.20.713290

    Figure Lengend Snippet: (A) Body weights of 8–12-week-old female C57BL/6N mice following intravenous administration of 1 mg/kg RNA formulated in LUNAR ® . (B–D) Plasma levels of PCSK9 protein (B), low-density lipoprotein cholesterol (LDL-C) (C), and total cholesterol (D) measured at indicated time points post-dosing. (E) Comparison of therapeutic efficacy of different gene-modifying modalities on plasma PCSK9, LDL-C, and total cholesterol levels at day 30 post-dose. Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparisons test (* P < 0.05, *** P < 0.001). For PCSK9 comparisons, differences between groups not specifically indicated are all statistically significant ( P < 0.001). Error bars: SD.

    Article Snippet: Plasma low-density lipoprotein cholesterol (LDL-C) was measured using a colorimetric assay kit (Novus Biologicals, Centennial, CO) following the manufacturer’s protocol, with samples loaded undiluted.

    Techniques: Clinical Proteomics, Comparison, Drug discovery

    (A) Experimental design comparing the efficacy of epi-editor delivery between the Capelluti et al. study and Arcturus Therapeutics. Plasma was collected at the indicated time points (dots colored by time). (B) Plasma PCSK9 levels measured at each time point post-dosing. Data were normalized to the respective vehicle controls (PBS-treated mice for Capelluti et al. and LUNAR ® -formulated eGFP mRNA for Arcturus data). (C–E) Comparison of plasma PCSK9 (C), LDL-C (D), and total cholesterol (E) at day 30 post-dosing. Values were normalized to the respective vehicle controls. Error bars: SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test (* P < 0.05, ** P < 0.01, *** P < 0.001). Capelluti’s data were adapted from provided data in and Arcturus data were from the current study.

    Journal: bioRxiv

    Article Title: Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable Pcsk9 Silencing in a Clinically Relevant Delivery System

    doi: 10.64898/2026.03.20.713290

    Figure Lengend Snippet: (A) Experimental design comparing the efficacy of epi-editor delivery between the Capelluti et al. study and Arcturus Therapeutics. Plasma was collected at the indicated time points (dots colored by time). (B) Plasma PCSK9 levels measured at each time point post-dosing. Data were normalized to the respective vehicle controls (PBS-treated mice for Capelluti et al. and LUNAR ® -formulated eGFP mRNA for Arcturus data). (C–E) Comparison of plasma PCSK9 (C), LDL-C (D), and total cholesterol (E) at day 30 post-dosing. Values were normalized to the respective vehicle controls. Error bars: SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test (* P < 0.05, ** P < 0.01, *** P < 0.001). Capelluti’s data were adapted from provided data in and Arcturus data were from the current study.

    Article Snippet: Plasma low-density lipoprotein cholesterol (LDL-C) was measured using a colorimetric assay kit (Novus Biologicals, Centennial, CO) following the manufacturer’s protocol, with samples loaded undiluted.

    Techniques: Clinical Proteomics, Comparison

    Effect of fetal Intralipid infusion on serum metabolic parameters. (A) Serum glucose concentrations. (B) Serum triglyceride (TG) concentrations. (C) Serum total cholesterol concentrations. (D) Serum low‐density lipoprotein cholesterol (LDL‐C) concentrations. (E) Serum high‐density cholesterol (HDL‐C) concentration. (Control group: N = 2F, 6M; Intralipid‐treated group: N = 6F, 3M; data are presented as mean ± SD; * p < 0.05, ** p < 0.01).

    Journal: The FASEB Journal

    Article Title: Intralipid Infusion to Fetal Sheep ( Ovis aries ) Promotes Differentiation and Lipid Accumulation of Adipose Tissues

    doi: 10.1096/fj.202502000R

    Figure Lengend Snippet: Effect of fetal Intralipid infusion on serum metabolic parameters. (A) Serum glucose concentrations. (B) Serum triglyceride (TG) concentrations. (C) Serum total cholesterol concentrations. (D) Serum low‐density lipoprotein cholesterol (LDL‐C) concentrations. (E) Serum high‐density cholesterol (HDL‐C) concentration. (Control group: N = 2F, 6M; Intralipid‐treated group: N = 6F, 3M; data are presented as mean ± SD; * p < 0.05, ** p < 0.01).

    Article Snippet: Measurement of serum biochemical parameters, including triglycerides (TG), high‐density lipoprotein cholesterol (HDL‐C), and low‐density lipoprotein cholesterol (LDL‐C), was performed according to the manufacturers' instructions using commercially available assay kits (Novus Biologicals, Centennial, CO, USA; catalog numbers NBP3‐24542, NBP3‐25823, and NBP3‐25881, respectively).

    Techniques: Concentration Assay, Control